About me
Stephen Lam was hired in 2024 as the CEO of Tanvex, with responsibility for establishing successful operations of the large molecule CDMO strategic alliance between Tanvex and Bora. With over 35 years in the biopharmaceutical industry at leading companies including Lonza, Amgen, and Patheon, Mr. Lam has built a strong track record of delivering results. He will lead the newly merged organization, ensuring a seamless integration of Bora’s robust operational resources and client-centric culture with Tanvex’s proven development and manufacturing capabilities.
